{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-006757","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.377111+00:00","generated_at":"2026-05-25T01:39:05.220128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"UroGen reports Q4/FY2024: JELMYTO rev $90.4M; net loss $126.9M; guides FY2025 rev $94-98M","bullets":["UGN-102 NDA under FDA review; PDUFA June 13, 2025; 18-month DOR 80.6% in Phase 3 ENVISION trial.","JELMYTO net product revenue $90.4M in FY2024, up 9% YoY; underlying demand revenue grew 12% (FY) and 15% (Q4).","Net loss Q4 2024 $37.5M ($0.80/share) vs $26.0M ($0.72/share) in Q4 2023; FY net loss $126.9M ($2.96/share) vs $102.2M ($3.55/share).","FY2025 guidance: JELMYTO revenue $94-98M; operating expenses $215-225M (incl. $11-14M share-based comp).","Cash, equivalents and marketable securities $241.7M at Dec 31, 2024, up from $141.5M at Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-006757","json":"https://secwatch.observer/filing/0001437749-25-006757.json","markdown":"https://secwatch.observer/filing/0001437749-25-006757.md","text":"https://secwatch.observer/filing/0001437749-25-006757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/0001437749-25-006757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/urgn20250304_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:39:05.220128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}